Community-acquired MRSA leaps upward among children

Article

National report - The number of cases of community-acquired methicillin-resistant Staphylococcus aureus (CAMRSA) among healthy American children has risen exponentially over the past few years, and resistant strains of S. aureus appear to be more virulent than non-resistant strains.

Related Videos
Related Content

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023
© 2023 MJH Life Sciences

All rights reserved.